Compare KBH & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KBH | IRON |
|---|---|---|
| Founded | 1957 | 2017 |
| Country | United States | United States |
| Employees | 2384 | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.0B |
| IPO Year | 1987 | N/A |
| Metric | KBH | IRON |
|---|---|---|
| Price | $56.86 | $79.21 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 13 |
| Target Price | $64.45 | ★ $108.85 |
| AVG Volume (30 Days) | ★ 1.5M | 648.0K |
| Earning Date | 12-18-2025 | 11-06-2025 |
| Dividend Yield | ★ 1.77% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.15 | N/A |
| Revenue | ★ $6,236,214,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.45 | N/A |
| P/E Ratio | $9.17 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $48.90 | $30.82 |
| 52 Week High | $72.64 | $99.50 |
| Indicator | KBH | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 36.33 | 36.31 |
| Support Level | $56.02 | $76.24 |
| Resistance Level | $57.29 | $80.32 |
| Average True Range (ATR) | 1.45 | 4.03 |
| MACD | -0.56 | -1.17 |
| Stochastic Oscillator | 8.54 | 32.01 |
KB Home is an American construction company that focuses on residential construction in the United States. The company builds single-family homes and communities across different geographical segments which include the West Coast which also derives the majority of the revenue, Southwest, Central, and Southeast. The company operates in several markets and focuses on first-time and move-up homebuyers. It also invests in land acquisition and development to support future building activities and is also engaged in financial services operations which includes providing mortgage banking services through its joint venture with a third party.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.